secwatch / observer
8-K filed September 6, 2022, 7:59 PM ET ticker EVH CIK 0001628908
leadership confidence high sentiment neutral materiality 0.60

Evolent Health names Dan McCarthy as President; director Frank Williams not to stand for re-election

Evolent Health, Inc.

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Frank Williams

Director
EVH · Evolent Health, Inc.
Filed
September 6, 2022, 7:59 PM ET
In addition, on September 6, 2022, the Company announced that Frank Williams has expressed his intent not to stand for re-election at the Company’s 2023 Annual Meeting.
Role change

Dan McCarthy

President
EVH · Evolent Health, Inc.
Effective
2022-09-15
Filed
September 6, 2022, 7:59 PM ET
On September 1, 2022, Evolent Health, Inc. (the “Company”) announced that Dan McCarthy has been named President of the Company, effective September 15, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Frank Williams departed as Director at Evolent Health, Inc..

Action
will not stand for re-election
Role
Director
Exact text from the filing
In addition, on September 6, 2022, the Company announced that Frank Williams has expressed his intent not to stand for re-election at the Company’s 2023 Annual Meeting.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Dan McCarthy was named as President at Evolent Health, Inc..

Action
named
Role
President
Exact text from the filing
On September 1, 2022, Evolent Health, Inc. (the “Company”) announced that Dan McCarthy has been named President of the Company, effective September 15, 2022.
View on SEC.gov

Evolent Health, Inc. filing history →

Source: SEC EDGAR
accession 0001628908-22-000129
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.